$184.50 $0.89 (0.5%)

04:00 PM EST on 11/18/19

Allergan Plc (NYSE:AGN)

CAPS Rating: 4 out of 5

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products.

Current Price $184.50 Mkt Cap $60.6B
Open $183.45 P/E Ratio 0.00
Prev. Close $183.61 Div. (Yield) $2.96 (1.6%)
Daily Range $183.45 - $184.90 Volume 863,697
52-Wk Range $114.27 - $184.90 Avg. Daily Vol. 2,188,030

Caps

How do you think NYSE:AGN will perform against the market?

Add Stock to CAPS Watchlist

All Players

398 Outperform
28 Underperform
 

All-Star Players

93 Outperform
8 Underperform
 

Wall Street

17 Outperform
0 Underperform
 

Top NYSE:AGN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

bradford86 (99.77)
Submitted January 14, 2012

276. Watson Pharmaceuticals (NYSE: WPI) is down from $70 where it topped in 2011. At the present price of around $62, I think that there is a little upside here. Target: $63-$68. My 2012 EPS estimate is $5.60 which puts this at a P/E of 11.1 for a… More

naughtyguy (37.02)
Submitted March 13, 2014

34 billion market cap! You have got to be kidding!

Recent Community Commentary

Read the most recent pitches from players about AGN.

Recs

0
Member Avatar jsn1080 (34.09) Submitted: 5/22/2018 2:01:17 PM : Outperform Start Price: $151.44 NYSE:AGN Score: +7.82

This is a value play

Forward P/E: 9.29

Price to book: 0.74

Debt to Capital: 26.0%

Interest Coverage: 5 (est based on Forward P/E)

Forward Dividend : 1.73%

Payout Ratio: 18%

Credit Rating: BBB

Recs

0
Member Avatar XMFRendezvous (93.21) Submitted: 4/21/2018 6:48:15 PM : Outperform Start Price: $154.54 NYSE:AGN Score: +2.63

Mr. Market has been tough on a few biotechs recently. Botox has been Allergan's cash cow. They have excellent long term focused management (as seen in Valeant documentary) and are starting to develop Biosimilar drugs through acquisition which is the future of reducing costs of health care and should expand their market. It is the anti-Valeant model.

This and Celgene might be my favorite bigger biotech companies.

Recs

0
Member Avatar 401ktimer1 (98.33) Submitted: 12/27/2017 3:03:12 PM : Outperform Start Price: $160.72 NYSE:AGN Score: -1.98

Undervalued based on DCF:

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-agn/allergan#close

Leaderboard

Find the members with the highest scoring picks in AGN.

Score Leader

darkstrike2

darkstrike2 (< 20) Score: +893.25

The Score Leader is the player with the highest score across all their picks in AGN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
rustat82 68.63 11/22/2006 Outperform 1Y $23.78 +675.71% +135.13% +540.58 0 Comment
Sempre57 28.36 11/22/2006 Outperform 3W $24.02 +668.10% +135.06% +533.04 0 Comment
blazin1 < 20 11/21/2006 Outperform 3M $24.05 +667.07% +135.56% +531.50 0 Comment
snoopaloop 32.87 11/20/2006 Outperform 5Y $24.08 +666.15% +136.15% +530.00 0 Comment
trustee74 84.91 12/8/2006 Outperform 3Y $24.35 +657.73% +135.11% +522.61 0 Comment
NetscribePhrmtcl 79.47 1/17/2007 Outperform 1Y $24.68 +647.45% +131.84% +515.61 2 Comments
IBSpud < 20 1/12/2007 4/19/2012 Outperform 3Y $24.85 +642.56% +132.24% +510.32 0 Comment
JockDasher 48.78 1/12/2007 Outperform 1Y $24.89 +641.13% +133.04% +508.09 0 Comment
tdchayes 88.55 10/10/2006 Outperform 3M $24.62 +649.48% +144.77% +504.71 0 Comment
stockssmocks 89.91 10/15/2008 Outperform NS $22.19 +731.57% +228.38% +503.19 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for AGN.